Robert Collins

TL;DR: It is demonstrated that therapeutic dosing of INCB3344 significantly reduces disease in mice subjected to experimental autoimmune encephalomyelitis, a model of multiple sclerosis, as well as a rat model of inflammatory arthritis, which support targeting this receptor for the treatment of chronic inflammatory diseases.

TL;DR: In this article, a small molecule inhibitor of JAK1 and JAK2 was used to neutralize systemic cytokine neutralization in psoriasis patients, and the results showed that topical administration of INCB018424, a small-molecule inhibitor of the JAK/signal transducers and activators of transcription (STAT) signaling and the resultant production of inflammatory proteins (e.g., IL-17, monocyte chemotactic protein-1, and IL-22) in lymphocytes and monocytes, with half-maximal inhibitory

TL;DR: The preclinical properties described here provide the mechanism of action and support clinical investigations of parsaclisib as a therapy for B-cell malignancies and may be useful in guiding further translational studies for the selection of patients with DLBCL who might benefit from PI3Kδ inhibitor treatment in future trials.

TL;DR: This is the first manuscript describing itacitinib as a potent and selective JAK1 inhibitor with anti-inflammatory activity across multiple preclinical disease models and these data support the scientific rationale for ongoing clinical trials studying itacITinib in select GvHD patient populations.